

Remarks

Claims 34-36 and 74-76 have been amended. New dependent claims 80 and 81 have been added. Claims 34-36, 38, 40-41, and 74-81 are pending upon entry of the Reply and Amendment.

Applicants respectfully note that the Examiner renumbered claims 74-79 (page 2 of Office action dated June 29, 2007) but does not appear to have explicitly rejected claim 74 (Office action Summary and page 3 of Office action). Applicants have interpreted that all pending claims stand rejected.

The Examiner has suggested "indicating the energy is stopped during the interval . . . in order to overcome this rejection." Office action at page 3. Following a telephone interview on August 24, 2007 (memorialized by the Examiner on September 10, 2007), Applicants understood that agreement has been reached on an Amendment to add the phrase "activating the ablating element after the determining step is completed" to the independent claims. Specifically, Applicants understood that the agreed upon claim language would define over the art then currently cited.

In accordance with language discussed during the telephone interview, Applicants have amended independent claims 34 and 74 to include the phrase "activating the ablating element after the determining step is completed."

Support for the amendments to claims 34 and 74 is found in the specification as a whole and, for example, page 34, line 3 - page 36, line 5 of Applicants' specification as filed on February 18, 2000. The specification notes that when assessing the temperature response, the amount of energy delivered to the tissue at that time may be used to characterize the tissue (page 35, lines 25-27). The temperature response and tissue characterization steps are described on page 35, lines 4-27. Ablation, which stops after a predetermined time interval, is described at page 35, line 30 to page 36, line 3. Support for new claims 80 and 81 is found on page 35, line 5 of Applicants'

specification as filed. All references to the specification in this document are to the application as filed.

No new matter is introduced by these amendments.

Rejections under 35 U.S.C. § 103(a)

Claims 34-38 and 40 and 75-88 stand rejected as obvious over Rittman in combination with Swanson.

In the Office action of June 29, 2007, the Examiner alleges Applicants' previous amendment "does not define over the actual process occurring during the operation of the device of Rittman, III, et. al." (Office action at page 2).

In accordance with the Examiner's suggestion (Office action at page 3), Applicants have amended claims 34 and 74 to make it clear that "activating the ablation element [occurs] after the determining step is completed." No new matter is introduced by these amendments. As noted above, the specification recites that when assessing the temperature response, the amount of energy delivered to the tissue at that time may be used to characterize the tissue (page 35, lines 25-27). The temperature response and tissue characterization steps are described on page 35, lines 4-27. Ablation, which stops after a predetermined time interval, is described at page 35, line 30 to page 36, line 3.

Applicants submit that the distinct temperature measuring step in the claims as amended is neither taught nor suggested by Rittman or Swanson. Therefore, claims 34-36, 38, 40 and 74-88 are patentable over the cited combination.

Claim 41 and 73 stand rejected as obvious over Rittman in combination with Swanson and further in view of Ben Haim.

As noted above, Applicants have amended claims 41 and 73 to make it clear that that "activating the ablation element [occurs] after the determining step is completed."

Application No: 09/507,336
Attorney Docket No. 0E-040013US/82410.0027
Request for Continued Examination dated October 31, 2007

Since Ben Haim does not teach or suggest a "temperature measurement" step distinct from the ablation step, claims 41 and 73 are patentable over the additional Ben Haim reference. The rejection based on obviousness should be withdrawn.

Applicants request withdrawal of the Examiner's rejections and submit that the application is in condition for allowance. Timely notification of allowability is requested.

Applicants believe that a telephone conference with the Examiner would be of assistance in advancing the Application and respectfully request that the Examiner grant an interview before issuance of the next Office communication. Applicants will contact the Examiner to schedule the request.


Application No: 09/507,336
Attorney Docket No. 0E-040013US/82410.0027
Request for Continued Examination dated October 31, 2007

Applicants believe this response and Request for Continued Examination is timely filed within the one month date of the Advisory Action. Applicants have included the requisite fees for a Request for Continued Examination. No additional fees, requests for extension of time, other petitions, additional claim fees, or any other fees are believed to be necessary to enter and consider this paper. If, however, any extensions of time are required or any fees are due in order to enter or consider this paper or enter or consider any paper accompanying this paper, including fees for net addition of claims, Applicants hereby request any extensions or petitions necessary and the Commissioner is hereby authorized to charge our Deposit Account No. 50-1129 for any fees. If there is any variance between the fee submitted and any fee required, or if the payment or fee payment information has been misplaced or is somehow insufficient to provide payment, the Commissioner is hereby authorized to charge or credit Deposit Account No. 50-1129.

Respectfully submitted,

WILEY REIN LLP

Date: October 31, 2007

By: 
David J. Kulik
Reg. No. 36,576
Andrew P. Zager
Reg. No. 48,058

WILEY REIN LLP
Attn: Patent Administration
1776 K Street, N.W.
Washington, D.C. 20006
Telephone: 202.719.7000
Facsimile: 202.719.7049